Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T19:48:54.730Z.
Calculation as of: 2026-10-06T19:48:54.730Z.
Quote observation: 2026-10-06T19:45:20.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 310997c20848bd5012eb98bb82f11fa46ca59880ef1b58a452bebfeaa3e5ded1
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Phathom Pharmaceuticals, Inc.
Market Cap
$540.82M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$544.27M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$527.99M
Price/OCF Ratio
26.95
TTM Avg
30.64
3Y Avg
39.07
5Y Avg
39.07
Market Cap
$554.05M
Price/OCF Ratio
N/A
TTM Avg
41.16
3Y Avg
40.24
5Y Avg
16.59
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. (PHAT) | $540.82M | N/A | N/A | N/A | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $544.27M | N/A | N/A | N/A | N/A |
| Shattuck Labs, Inc. (STTK)vs › | $535.91M | N/A | N/A | N/A | N/A |
| ProKidney Corp. (PROK)vs › | $530.88M | N/A | N/A | N/A | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $525.25M | N/A | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $527.99M | 26.95 | 30.64 | 39.07 | 39.07 |
| Nuvectis Pharma, Inc. (NVCT)vs › | $528.61M | N/A | N/A | N/A | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $554.05M | N/A | 41.16 | 40.24 | 16.59 |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $516.33M | N/A | 0.26 | 0.26 | 0.26 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
